Loading...
•
Mar 31, 2023
Pacira Q1 2023 Earnings Report
Pacira BioSciences reported financial results for the first quarter of 2023.
Key Takeaways
Pacira BioSciences reported total revenues of $160.3 million in the first quarter of 2023. EXPAREL net product sales were $130.4 million, ZILRETTA net product sales were $24.3 million, and iovera° net product sales were $4.0 million. The company reported a GAAP net loss of $19.5 million, or $0.43 per share, and an adjusted EBITDA of $41.9 million.
Total revenues were $160.3 million.
EXPAREL net product sales were $130.4 million.
ZILRETTA net product sales were $24.3 million.
iovera° net product sales were $4.0 million.
Revenue by Segment
Forward Guidance
Pacira reiterated its full-year 2023 financial guidance.
Positive Outlook
- EXPAREL net product sales of $570 million to $580 million
- ZILRETTA net product sales of $115 million to $125 million
- iovera° net product sales of $17 million to $20 million
- Non-GAAP Gross margin of 76% to 78%
- Stock-based compensation of $51 million to $54 million.
Challenges Ahead
- Non-GAAP R&D expense of $70 million to $80 million
- Non-GAAP SG&A expense of $220 million to $230 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...